Display Settings:

Format

Send to:

Choose Destination
Pharmacol Biochem Behav. 2010 Nov;97(1):179-84. doi: 10.1016/j.pbb.2010.07.021. Epub 2010 Aug 14.

The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior.

Author information

  • 1Department of Psychology, University of Connecticut, Storrs, CT 06269-1020, USA.

Abstract

Drugs that interfere with cannabinoid CB1 transmission suppress food-motivated behaviors, and may be useful clinically as appetite suppressants. However, there may also be undesirable side effects (e.g., nausea, malaise, anxiety, and depression) that are produced by the current generation of CB1 inverse agonists such as rimonabant and taranabant. For that reason, it is important to continue research on novel cannabinoid antagonists. The present studies examined the effects of the novel compound AM6545, which is a neutral antagonist of CB1 receptors that is thought to have relatively poor penetrability into the central nervous system. Intraperitoneal administration of AM6545 significantly reduced food-reinforced operant responding at doses of 4.0, 8.0 and 16.0 mg/kg. AM6545 also produced a strong suppression of the intake of high-carbohydrate and high-fat diets in the same dose range, but only produced a mild suppression of lab chow intake at the highest dose (16.0 mg/kg). Although AM6545 did not affect food handling, it did reduce time spent feeding and feeding rate. Taken together, these results suggest that AM6545 is a compound that warrants further study as a potential appetite suppressant drug.

Copyright © 2010 Elsevier Inc. All rights reserved.

PMID:
20713079
[PubMed - indexed for MEDLINE]
PMCID:
PMC3522179
Free PMC Article

Images from this publication.See all images (3)Free text

Figure 1
Figure 2
Figure 3
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk